用固相多肽合成技术制备了特异性靶向肺癌干细胞的T1型多肽核磁共振成像（MRI）探针——Gd-DOTA-HCBP-1．在11.7 T静磁场条件下，其纵向弛豫效率（r1）为6.15 mmol-1·L·s-1，是商用T1造影剂Dotarem的1.6倍．体外细胞成像表明，此探针的使用可显著提高肺癌干细胞克隆球的可观测性，单个克隆球（包含2 000~4 000个细胞）可被明显辨识．
李春林
,
英晓芳
,
魏建东
,
张海禄
,
张宏岩
,
邓宗武
,
朱毅敏
,
谭波
. 靶向肺癌干细胞的多肽Gd基T1型MRI探针的研究[J]. 波谱学杂志, 2016
, 33(4)
: 627
-634
.
DOI: 10.11938/cjmr20160412
A T1 magnetic resonance imaging (MRI) contrast agent specific to lung cancer stem cells Gd-DOTA-HCBP-1 was synthesized by solid-phase peptide synthesis technology. Its longitudinal relaxation rate (r1) was 6.15 mmol-1·L·s-1, approximately 0.6 times higher than that of the commercial T1 contrast agents Dotarem at 11.7 T. In vitro MRI experiments indicated that the detectability of the cancer stem cells could be significantly improved to about 2 000~4 000 cells per sphere by the use of the probe.
[1] Reya T, Morrison S J, Clarke M F, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414(6859):105-111.
[2] Alent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology:the devil is in the details[J]. Nat Rev Cancer, 2012, 12(11):767-775.
[3] Visvader J E, Lindeman G J. Cancer stem cells in solid tumours:Accumulating evidence and unresolved questions[J]. Nat Rev Cancer, 2008, 8(10):755-768.
[4] Gillies R J, Bhujwalla Z M, Evelhoch J, et al. Applications of magnetic resonance in model systems:Tumor biology and physiology[J]. Neoplasia, 2000, 2(1, 2):139-151.
[5] Pautler R G. Mouse MRI:Concepts and applications inphysiology[J]. Physiol, 2004, 19(4):168-175.
[6] Persigehl T, Heindel W, Bremer C. MR and optical approaches to molecular imaging[J]. Abdom Imaging, 2005, 30(3):342-354.
[7] Fani M, Maeche H R, Okarvi S M. Radiolabeled peptides:Valuable tools for the detection and treatment of cancer[J]. Theranostics, 2012, 2(5):481-501.
[8] Wang A, Chen L, Pu K, et al. Identification of stem-like cells in non-small cell lung cancer cells using specific peptides[J]. Cancer Lett, 2014, 351(1):100-107.
[9] Li C, Winnard P, Bhujwalla Z M. Facile synthesis of 1-(acetic acid)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane:A reactive precursor chelating agent[J]. Tetrahedron Lett, 2009, 50(24):2929-2931.
[10] Visvader J E, Lindeman G J. Cancer stem cells in solid tumours:Accumulating evidence and unresolved questions[J]. Nat Rev Cancer, 2008, 8(10):755-768.
[11] Arbab A S, Liu W, Frank J A. Cellular magnetic resonance imaging:Current status and future prospects[J]. Expert Rev Med Devic, 2006, 3(4):427-439.
